Knight Therapeutics Raises FY2026 Sales Guidance from $540.000M-$560.000M to $560.000M-$570.000M vs $552.380M Est

Benzinga · 23h ago
Knight Therapeutics (TSX:GUD) raises FY2026 sales outlook from $540.000 million-$560.000 million to $560.000 million-$570.000 million vs $552.380 million estimate.